Get the Daily Brief
Latest Biotech News
Pancreatic cancer RAS targeting expands with new first-line and combination data
Revolution Medicines delivered updated evidence for daraxonrasib, its oral multi-selective inhibitor targeting RAS, at AACR, adding first-line and combination readouts in metastatic pancreatic...
Pancreatic cancer chemo-resistance faces new leverage via netrin-1 inhibition
Netris Pharma reported positive Phase Ib data for NP-137, a first-in-class inhibitor of netrin-1, targeting chemotherapy resistance in pancreatic cancer. The company’s update centers on the...
FDA approval opens competition in second-line HIV with Merck’s once-daily regimen
The FDA cleared Merck’s Idvynso (doravirine/islatravir), giving providers a new once-daily option for adults with HIV-1 who are already virologically suppressed and have no history of treatment...
Autoimmune CAR-T pushes toward FDA filing after full SPS dataset from Kyverna
Kyverna Therapeutics advanced its stiff-person syndrome (SPS) CAR T effort with full registrational trial results for mivocabtagene autoleucel (miv-cel, KYV-101). The company published a...
Medicare obesity drug coverage stalls as CMS delays BALANCE model
The U.S. Centers for Medicare & Medicaid Services indefinitely delayed the BALANCE pilot model after insurance plans did not commit to participate in covering obesity drugs under Medicare Part D....
CNS biotech Tortugas raises $106M to advance oral brain disorder pipeline
Tortugas Neurosciences raised $106 million across seed and Series A rounds to develop oral small-molecule candidates for multiple CNS disorders. The company plans to complete Phase II work for two...
Neurodevelopment and gene therapy advance: antisense treatment targets ultra-rare HNRNPH2 disorder
St. Jude Children’s Research Hospital reported preclinical evidence for an antisense oligonucleotide (ASO) strategy designed to reverse a neurodevelopmental disorder linked to HNRNPH2 mutations....
Gene therapy for DFNB9 deafness reports long-term multicentre outcomes
Researchers reported long-term results from a multicentre gene therapy trial targeting autosomal recessive deafness 9 (DFNB9), a severe congenital hearing loss caused by mutations in OTOF. The...
Biopharma dealmaking: Biogen consolidates felzartamab rights with $850M TJ Biopharma agreement
Biogen agreed to consolidate full global rights to felzartamab by entering an $850 million deal with TJ Biopharma covering Greater China exclusivity. The transaction includes a $100 million...
Clinical diagnostics: ClearNote improves pancreatic cancer early detection test sensitivity with added biomarker
ClearNote Health advanced its pancreatic cancer early detection platform, presenting updated performance for its Avantect Pancreatic Cancer test at AACR. The update adds an additional biomarker to...
FDA approval expands Merck’s HIV franchise
The FDA approved Merck & Co.’s Idvynso (doravirine/islatravir), a once-daily two-drug HIV regimen for adults with HIV-1 who are virologically suppressed and meet specific resistance criteria. The...
Pancreatic cancer: Netris’ netrin-1 inhibitor targets chemo resistance
Netris Pharma reported positive Phase Ib data for its first-in-class netrin-1 inhibitor NP-137 in pancreatic ductal adenocarcinoma, showing activity against chemotherapy resistance. The company’s...
AACR momentum for Revolution Medicines’ RAS strategy in PDAC
Revolution Medicines continued to build momentum for its RAS-targeting approach in pancreatic cancer at the American Association for Cancer Research meeting. The company shared updated Phase I/II...
Autoimmune CAR-T: Kyverna posts full miv-cel dataset for stiff-person syndrome
Kyverna Therapeutics released the full registrational dataset for mivocabtagene autoleucel (miv-cel, KYV-101) in stiff-person syndrome from its KYSA-8 trial. The company highlighted rapid,...
Pancreatic cancer early detection: ClearNote adds biomarker to Avantect test
ClearNote Health advanced its commercialization plans for pancreatic cancer screening by presenting new performance data for its Avantect Pancreatic Cancer test after adding a glycan biomarker to...
Regulatory and payer shift in obesity drug coverage: CMS delays Medicare pilot
The U.S. Centers for Medicare and Medicaid Services indefinitely delayed a voluntary Medicare model intended to cover obesity drugs under its BALANCE framework, and instead extended a temporary...
Gene therapy supply chain: Andelyn links US and South Korea for global manufacturing
Andelyn Biosciences partnered with ENCell to build a manufacturing bridge connecting the United States and Asia-Pacific for cell and gene therapy programs. The companies said the collaboration is...
Biogen consolidates felzartamab rights via $850M China-region deal
Biogen struck an $850 million agreement with TJ Biopharma to secure exclusive felzartamab rights in the Greater China region, including a $100 million upfront payment and additional...
CGT manufacturing quality: viral contamination remains a core hurdle
A new analysis in the CGT manufacturing space highlights ongoing vulnerabilities around viral contamination, pointing to raw materials as the biggest source of risk. The report notes that...
Drugmaker disruption: Lilly scraps remaining Rigel RIPK1 collaboration
Eli Lilly terminated the remainder of its RIPK1 partnership with Rigel Pharmaceuticals, following an earlier pullback from a CNS-focused portion of the alliance. The latest move is framed as part...